Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial

BACKGROUND: Type 1 diabetes results from T-cell-mediated destruction of β cells. Findings from preclinical studies and pilot clinical trials suggest that antithymocyte globulin (ATG) might be effective for reducing this autoimmune response. We assessed the safety and efficacy of rabbit ATG in preser...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Lancet Diabetes Endocrinol
Autors principals: Gitelman, S E, Bluestone, J A, Gottlieb, P A, Rigby, M R, Felner, E I, Willi, S M, Fisher, L K, Moran, A, Gottschalk, M, Moore, W V, Pinckney, A, Keyes-Elstein, L, Aggarwal, S, Phippard, D, Sayre, P H, Ehlers, M R, Ding, L
Format: Artigo
Idioma:Inglês
Publicat: 2013
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6489466/
https://ncbi.nlm.nih.gov/pubmed/24622416
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2213-8587(13)70065-2
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars